CN107635580A - 治疗眼病的方法 - Google Patents

治疗眼病的方法 Download PDF

Info

Publication number
CN107635580A
CN107635580A CN201580060416.5A CN201580060416A CN107635580A CN 107635580 A CN107635580 A CN 107635580A CN 201580060416 A CN201580060416 A CN 201580060416A CN 107635580 A CN107635580 A CN 107635580A
Authority
CN
China
Prior art keywords
week
bcva
mammal
vegf
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580060416.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·索尔斯缇戈
W·施密特
M·戈奇瓦
J·沃伯顿
A·维奇塞尔伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107635580(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202111376360.8A priority Critical patent/CN114081951A/zh
Publication of CN107635580A publication Critical patent/CN107635580A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580060416.5A 2014-11-07 2015-11-06 治疗眼病的方法 Pending CN107635580A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111376360.8A CN114081951A (zh) 2014-11-07 2015-11-06 治疗眼病的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US62/076,770 2014-11-07
US201462088061P 2014-12-05 2014-12-05
US62/088,061 2014-12-05
PCT/US2015/059575 WO2016073918A1 (en) 2014-11-07 2015-11-06 Methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111376360.8A Division CN114081951A (zh) 2014-11-07 2015-11-06 治疗眼病的方法

Publications (1)

Publication Number Publication Date
CN107635580A true CN107635580A (zh) 2018-01-26

Family

ID=54697654

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201580060416.5A Pending CN107635580A (zh) 2014-11-07 2015-11-06 治疗眼病的方法
CN201580060665.4A Pending CN106999581A (zh) 2014-11-07 2015-11-06 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
CN202511153148.3A Pending CN120938921A (zh) 2014-11-07 2015-11-06 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
CN202111376360.8A Pending CN114081951A (zh) 2014-11-07 2015-11-06 治疗眼病的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201580060665.4A Pending CN106999581A (zh) 2014-11-07 2015-11-06 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
CN202511153148.3A Pending CN120938921A (zh) 2014-11-07 2015-11-06 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
CN202111376360.8A Pending CN114081951A (zh) 2014-11-07 2015-11-06 治疗眼病的方法

Country Status (25)

Country Link
US (5) US10689438B2 (enExample)
EP (3) EP4684797A2 (enExample)
JP (6) JP6667519B2 (enExample)
KR (4) KR20240161204A (enExample)
CN (4) CN107635580A (enExample)
AU (6) AU2015342818B2 (enExample)
BR (2) BR112017008660A2 (enExample)
CA (1) CA2966646A1 (enExample)
CL (2) CL2017001115A1 (enExample)
CO (1) CO2017004596A2 (enExample)
EA (1) EA201790989A1 (enExample)
EC (1) ECSP17034829A (enExample)
ES (1) ES3051145T3 (enExample)
GT (1) GT201700096A (enExample)
IL (5) IL251642B (enExample)
MX (3) MX383399B (enExample)
MY (2) MY183807A (enExample)
NZ (1) NZ730821A (enExample)
PE (1) PE20170780A1 (enExample)
PH (3) PH12021550147A1 (enExample)
RU (1) RU2722643C2 (enExample)
SG (3) SG10201913565RA (enExample)
TN (1) TN2017000128A1 (enExample)
TW (4) TWI705827B (enExample)
WO (2) WO2016073915A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111867631A (zh) * 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR101834797B1 (ko) 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
KR20210065201A (ko) 2008-06-25 2021-06-03 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
MX349901B (es) 2011-01-13 2017-08-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
CN107206080B (zh) 2015-01-28 2022-07-08 辉瑞公司 稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
CA3006432A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
JP6644956B2 (ja) * 2016-09-07 2020-02-12 サクシン ライフサイエンシス ピーヴィーティー エルティディーＳａｋｓｉｎ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｐｖｔ Ｌｔｄ Ｖｅｇｆに対する合成の抗体およびそれらの使用
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN109562166B (zh) * 2017-04-28 2021-04-02 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
SG11202002490UA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Methods of detecting transthyretin
WO2019071205A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited ANTI-TRANSTHYRETIN ANTIBODY
EP3717512A4 (en) * 2017-11-29 2021-08-25 Prothena Biosciences Limited LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETIN
MX2020005166A (es) 2017-11-30 2020-09-03 Regeneron Pharma Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
IL310376B1 (en) 2018-01-26 2025-10-01 Univ California Methods and compositions for treating angiogenic disorders using anti-VEGF factors
CN119909169A (zh) * 2018-02-06 2025-05-02 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
MX2020009935A (es) * 2018-03-23 2021-01-08 Abbvie Deutschland Formulaciones acuosas y estables de anticuerpos anti-tau.
WO2019200006A2 (en) * 2018-04-10 2019-10-17 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
AU2019265005B2 (en) 2018-05-10 2025-03-13 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CA3100317A1 (en) 2018-05-17 2019-11-21 Astellas Pharma Inc. Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
EP3856245A4 (en) * 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020075746A1 (ja) * 2018-10-10 2020-04-16 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
BR112021007946A2 (pt) * 2018-10-29 2021-08-03 F. Hoffmann-La Roche Ag formulação de anticorpo
MX2021005382A (es) 2018-11-07 2021-11-12 Applied Molecular Transport Inc Vehiculos derivados de cholix para suministro oral de carga util heterologa.
AR117707A1 (es) * 2018-12-18 2021-08-25 Novartis Ag Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
CN113474360B (zh) 2019-02-18 2025-01-07 伊莱利利公司 治疗性抗体制剂
TWI862583B (zh) 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
KR20220066056A (ko) 2019-08-16 2022-05-23 어플라이드 몰레큘라 트랜스포트 인크. 조성물, 제형, 및 인터루킨 제조 및 정제
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
US20230192832A1 (en) * 2020-03-04 2023-06-22 Shanghai Henlius Biotech, Inc. Pharmaceutical formulation comprising bevacizumab
CN113698478B (zh) * 2020-05-21 2025-11-18 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
CR20230009A (es) 2020-07-16 2023-01-25 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
EP4185318B1 (en) * 2021-05-17 2025-09-03 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
JP2025529465A (ja) * 2022-09-16 2025-09-04 チールー ファーマシューティカル カンパニー、リミテッド 安定な高濃度自己緩衝医薬組成物
WO2025231345A1 (en) * 2024-05-03 2025-11-06 Therini Bio, Inc. Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311433A2 (en) * 2004-10-21 2011-04-20 Genentech, Inc. Method for treating intraocular neovascular diseases
CN102143976A (zh) * 2008-06-25 2011-08-03 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制vegf的稳定和可溶的抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI2364691T1 (sl) * 2006-06-16 2013-08-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
KR20210065201A (ko) 2008-06-25 2021-06-03 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
KR101834797B1 (ko) 2008-06-25 2018-03-07 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
JP5988580B2 (ja) 2008-06-30 2016-09-07 エスバテック − ア ノバルティス カンパニー エルエルシー 機能性ポリペプチド
CN102770158B (zh) 2009-12-21 2016-10-19 霍夫曼-拉罗奇有限公司 抗体配制剂
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
MX349901B (es) * 2011-01-13 2017-08-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
CN107090038A (zh) 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
TWI577696B (zh) * 2011-10-20 2017-04-11 Ｅｓｂａ科技 諾華有限責任公司 穩定的多重抗原結合抗體
NZ741873A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JOP20200175A1 (ar) 2012-07-03 2017-06-16 Novartis Ag حقنة
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
NZ751452A (en) 2013-03-13 2020-04-24 Genentech Inc Antibody formulations
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
BR112016029864A2 (pt) * 2014-06-17 2017-08-22 Clearside Biomedical Inc métodos e dispositivos para tratamento de desordens oculares posteriores.
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR20200131839A (ko) 2018-03-16 2020-11-24 노파르티스 아게 안질환의 치료 방법
AR117707A1 (es) 2018-12-18 2021-08-25 Novartis Ag Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311433A2 (en) * 2004-10-21 2011-04-20 Genentech, Inc. Method for treating intraocular neovascular diseases
CN102143976A (zh) * 2008-06-25 2011-08-03 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制vegf的稳定和可溶的抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IRMELA MANTEL，ET AL: "Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen", 《CLINICAL SCIENCE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111867631A (zh) * 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
AU2021286278B2 (en) * 2018-03-16 2023-09-14 Novartis Ag Methods for treating ocular diseases
AU2021286278C1 (en) * 2018-03-16 2024-05-23 Novartis Ag Methods for treating ocular diseases

Also Published As

Publication number Publication date
TWI806150B (zh) 2023-06-21
US20200270336A1 (en) 2020-08-27
WO2016073918A1 (en) 2016-05-12
AU2020220210B2 (en) 2022-01-20
EA201790989A1 (ru) 2017-09-29
US10035850B2 (en) 2018-07-31
IL283561B (en) 2022-01-01
RU2020114917A3 (enExample) 2022-01-17
TN2017000128A1 (en) 2018-10-19
ES3051145T3 (en) 2025-12-26
RU2017119647A3 (enExample) 2019-05-29
JP2017534638A (ja) 2017-11-24
TWI738632B (zh) 2021-09-11
EP3215122C0 (en) 2025-08-13
AU2015342818B2 (en) 2019-01-03
AU2018278870B2 (en) 2020-05-28
MX2017005875A (es) 2017-06-26
CN106999581A (zh) 2017-08-01
PE20170780A1 (es) 2017-07-04
IL280087A (en) 2021-03-01
KR102588846B1 (ko) 2023-10-16
JP6753848B2 (ja) 2020-09-09
MY183807A (en) 2021-03-16
CA2966758A1 (en) 2016-05-12
IL251642B (en) 2021-02-28
AU2020244614B2 (en) 2023-06-01
MX2021006768A (es) 2021-07-15
IL251696A0 (en) 2017-06-29
RU2722643C2 (ru) 2020-06-02
MX2017005874A (es) 2017-06-26
MX383399B (es) 2025-03-13
NZ730821A (en) 2019-11-29
GT201700096A (es) 2019-10-10
CN114081951A (zh) 2022-02-25
CL2017001115A1 (es) 2018-01-26
MY193913A (en) 2022-11-01
AU2020220210A1 (en) 2020-10-01
CA2966646A1 (en) 2016-05-12
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
JP2017538674A (ja) 2017-12-28
RU2017119647A (ru) 2018-12-07
RU2020114917A (ru) 2020-05-22
US12371481B2 (en) 2025-07-29
IL265497B (en) 2021-06-30
KR20240161204A (ko) 2024-11-12
US20180298092A1 (en) 2018-10-18
JP2025004075A (ja) 2025-01-14
US12049495B2 (en) 2024-07-30
AU2018274882A1 (en) 2018-12-20
TW201625221A (zh) 2016-07-16
IL251642A0 (en) 2017-06-29
PH12017500844A1 (en) 2017-10-30
US20160340420A1 (en) 2016-11-24
IL283561A (en) 2021-07-29
BR112017008660A2 (pt) 2017-12-26
PH12021550147A1 (en) 2023-01-23
US20210340242A1 (en) 2021-11-04
JP2020193212A (ja) 2020-12-03
MX383808B (es) 2025-03-14
TW202103735A (zh) 2021-02-01
AU2018274882B2 (en) 2020-07-09
TW202146049A (zh) 2021-12-16
EP4684797A2 (en) 2026-01-28
IL265497A (en) 2019-05-30
CO2017004596A2 (es) 2017-08-31
CN120938921A (zh) 2025-11-14
BR112017008093A2 (pt) 2018-03-13
EP3215122B1 (en) 2025-08-13
KR20230066649A (ko) 2023-05-16
IL280087B (en) 2022-02-01
EP3215122A1 (en) 2017-09-13
ECSP17034829A (es) 2019-02-28
AU2015342815A1 (en) 2017-05-11
WO2016073915A1 (en) 2016-05-12
TWI705827B (zh) 2020-10-01
EP3215123A1 (en) 2017-09-13
KR20170082526A (ko) 2017-07-14
SG11201702954XA (en) 2017-05-30
AU2020244614A1 (en) 2020-11-05
TWI761959B (zh) 2022-04-21
JP7080263B2 (ja) 2022-06-03
TW201625306A (zh) 2016-07-16
SG10201913565RA (en) 2020-02-27
US20160130337A1 (en) 2016-05-12
JP6667519B2 (ja) 2020-03-18
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
CL2017001117A1 (es) 2018-01-26
US11098110B2 (en) 2021-08-24
KR102724014B1 (ko) 2024-10-31
KR20170076781A (ko) 2017-07-04
PH12017500843A1 (en) 2017-10-30
PH12017500844B1 (en) 2021-05-05
AU2018278870A1 (en) 2019-01-03
JP2020079242A (ja) 2020-05-28
JP2022141923A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
US12371481B2 (en) Methods for treating age-related macular degeneration
AU2021286278C1 (en) Methods for treating ocular diseases
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
RU2771900C2 (ru) Способ лечения болезней глаз
US20230416351A1 (en) Vegf antagonist for use in methods for treating ocular diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180126